바이러스 벡터 및 플라스미드 DNA : 다양한 기술 및 세계 시장

The global market for viral vector and plasmid DNA technologies is expected to grow from $2.9 billion in 2023 to $7.1 billion by the end of 2028, at a compound annual growth rate (CAGR) of 19.7% from 2023 through 2028.

The global market for viral vector technology is expected to grow from $1.8 billion in 2023 to $4.5 billion by the end of 2028, at a CAGR of 20.7% from 2023 through 2028.

The global market for plasmid DNA technology is expected to grow from $1.1 billion in 2023 to $2.6 billion by the end of 2028, at a CAGR of 17.9% from 2023 through 2028.

Report Scope:

The report provides a comprehensive summary of the viral vector and plasmid DNA technologies market focusing cell and gene therapies, along with detailed competitive landscape and profiles of key market players that include revenue, product portfolios and recent activities. The report analyzes trends and dynamics, including drivers, limitations, challenges, and opportunities. This research study discusses historical, current, and potential market size. The report will enable market players and new entrants to make informed decisions about the production and licensing of goods and services. Organizations, distributors, and exporters should find the information about market development and trends useful. The study segments the market on the basis of product type, applications, and end use. Geographical market analysis is provided for all the major segments. The report offers country-level analysis of markets to provide a better understanding of the major segments.

The market is divided into segments and by application/industry as follows:

By product type:

Viral vector.

Plasmid DNA.

By application:

Cancer.

Genetic disorders.

Infectious diseases.

Cardiovascular diseases.

Other diseases.

By end-user:

Research institutes.

Pharmaceutical and biopharmaceutical companies.

Each area is covered in detail, identifying current products in the market in the base year (2022), measuring the current market size and identifying current and potential market drivers, forecasting for 2028, assessing current and potential competitors, and identifying current competitor market shares for 2022.

Report Includes:

• 93 data tables and 47 additional tables
• An overview of the global market for viral vector and plasmid DNA
• Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Evaluation of the current market size and revenue growth prospects for viral vector and plasmid DNA, along with a market share analysis by product type, application and geographic region
• A look at the innovations, technological advances, and product launches from leading companies
• Analysis of the industry's regulatory framework and policies, and its product pipeline
• Discussion of ESG challenges and ESG practices
• Analysis of the key companies' market shares, proprietary technologies, strategic alliances and other market strategies, and patents
• Profiles of the leading players in the industry

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Viral Technology
• Cell and Gene Therapy

Chapter 3 Market Dynamics

• Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges

Chapter 4 Emerging Technologies and Developments

• Overview
• AI in Viral Vector Production
• Doggy Bone DNA
• FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
• Patents
• Patent Holdings by Manufacturer
• Clinical Trials
• Selected Clinical Trials of Viral Vectors and Plasmid DNA Technologies

Chapter 5 Global Market for Viral Vector and Plasmid DNA Technologies

• Segmentation Breakdown
• Market Breakdown by Product Type
• Market Breakdown by End User
• Research Institutes
• Pharmaceutical and Biopharmaceutical Companies
• Market Breakdown by Application
• Cancer
• Genetic Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Other Diseases
• Geographic Breakdown
• Market Breakdown by Region
• North America
• Latin America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 6 Competitive Intelligence

• Industry Scenario
• Company Shares
• Competitive Landscape among Companies
• Competitive Landscape in Viral Vectors
• Competitive Landscape in Plasmid DNA

Chapter 7 Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective

• Introduction
• Environmental Factors
• Social Factors
• Governance Factors
• ESG Performance among Major Companies
• ESG Performance of Select Companies
• Lonza: ESG Performance
• Thermo Fisher Scientific: ESG Performance
• Conclusion

Chapter 8 Appendix

• Research Methodology
• Acronyms
• References
• Company Profiles
• AGILENT TECHNOLOGIES INC.
• BLUEBIRD BIO INC.
• CATALENT INC.
• DANAHER CORP.
• FUJIFILM HOLDINGS CORP.
• GENSCRIPT
• GILEAD SCIENCES INC.
• LONZA
• NOVARTIS AG
• OXFORD BIOMEDICA PLC
• PLASMIDFACTORY GMBH
• REGENXBIO INC.
• THERMO FISHER SCIENTIFIC INC.
• VGXI INC.